• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Compliance with timolol treatment in glaucoma.

作者信息

Rotchford A P, Murphy K M

机构信息

Hlabisa Hospital, KwaZulu-Natal South Africa.

出版信息

Eye (Lond). 1998;12 ( Pt 2):234-6. doi: 10.1038/eye.1998.56.

DOI:10.1038/eye.1998.56
PMID:9683946
Abstract

PURPOSE

To assess levels of compliance in elderly patients on timolol eyedrops for glaucoma.

METHODS

A postal questionnaire was sent from the general practitioner to 86 patients over 55 years of age on repeat prescriptions for timolol eyedrops. The questionnaire asked details about the duration of treatment, family history, the level of understanding of the disease and the importance of treatment, other regular medication, side-effects attributed to the drops and how often patients omitted their drops. A search of practice and local hospital dispensing data was carried out to assess how frequently monthly repeat prescriptions for timolol eyedrops were dispensed over a 12 month period. This allowed a total volume to be calculated for each patient.

RESULTS

Twenty-four per cent of patients admitted to omitting eyedrops either occasionally or frequently. Fifty-one per cent were found to have had insufficient drops dispensed to comply with treatment as prescribed. In non-complaint patients the mean period without drops was 85 days of the year, with a maximum of 165 days.

CONCLUSION

Compliance with treatment is poor and patients underestimate their level of defaulting when questioned.

摘要

相似文献

1
Compliance with timolol treatment in glaucoma.
Eye (Lond). 1998;12 ( Pt 2):234-6. doi: 10.1038/eye.1998.56.
2
[Timolol eyedrops in ophthalmological practice].[噻吗洛尔滴眼液在眼科临床中的应用]
Klin Monbl Augenheilkd. 1980 Mar;176(3):430-40. doi: 10.1055/s-2008-1057474.
3
Discontinuation rates of topical glaucoma medications in a managed care population.管理式医疗人群中局部用青光眼药物的停药率。
Am J Manag Care. 2002 Aug;8(10 Suppl):S271-7.
4
Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma.在高眼压症或开角型青光眼患者中,患者对马来酸噻吗洛尔眼用凝胶剂与马来酸噻吗洛尔滴眼液的偏好、疗效及依从性比较
Clin Ther. 1999 Jan;21(1):138-47. doi: 10.1016/S0149-2918(00)88274-0.
5
Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.从拉坦前列素转换为拉坦前列素-噻吗洛尔固定复方制剂:一项针对青光眼和高眼压症患者的为期21天的随机、双盲、活性对照研究。
Clin Ther. 2004 Oct;26(10):1619-29. doi: 10.1016/j.clinthera.2004.10.009.
6
Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination.使用 Travatan 给药辅助装置监测青光眼患者的用药依从性。一项为期 6 个月的研究比较了使用 0.004% travoprost 患者和使用 0.004% travoprost/0.5% timolol 固定组合的患者。
Expert Opin Pharmacother. 2010 Mar;11(4):499-504. doi: 10.1517/14656561003601994.
7
The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients.双氯芬酸眼药水对原发性开角型青光眼患者局部使用0.5%噻吗洛尔和0.005%拉坦前列素降眼压效果的影响。
Exp Eye Res. 2005 Nov;81(5):610-5. doi: 10.1016/j.exer.2005.03.020. Epub 2005 Jun 8.
8
[Are 0.1% timolol-maleate eyedrops suitable for treating chronic glaucoma? (author's transl)].
Klin Monbl Augenheilkd. 1982 Feb;180(2):141-5. doi: 10.1055/s-2008-1055034.
9
[2-year long-term treatment of chronic glaucoma with timolol eyedrops].
Bull Soc Ophtalmol Fr. 1979 Jun-Jul;79(6-7):615-21.
10
Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure.噻吗洛尔每日一次与拉坦前列素对眼压夜间影响的比较。
Am J Ophthalmol. 2004 Sep;138(3):389-95. doi: 10.1016/j.ajo.2004.04.022.

引用本文的文献

1
Contact lens as an emerging platform for ophthalmic drug delivery: A systematic review.隐形眼镜作为眼科药物递送的新兴平台:一项系统评价。
Asian J Pharm Sci. 2023 Sep;18(5):100847. doi: 10.1016/j.ajps.2023.100847. Epub 2023 Sep 27.
2
[Awareness for glaucoma in the general population].[普通人群对青光眼的认知情况]
Ophthalmologie. 2023 Nov;120(11):1088-1097. doi: 10.1007/s00347-023-01943-0. Epub 2023 Oct 17.
3
Adherence of patients with age-related macular degeneration to AREDS 2-recommended nutritional supplements.年龄相关性黄斑变性患者对 AREDS2 推荐营养补充剂的依从性。
Ir J Med Sci. 2023 Dec;192(6):3163-3167. doi: 10.1007/s11845-023-03351-4. Epub 2023 Mar 27.
4
Assessment of the readability and quality of online patient education materials for the medical treatment of open-angle glaucoma.评估用于开角型青光眼治疗的在线患者教育材料的可读性和质量。
BMJ Open Ophthalmol. 2022 Mar 28;7(1):e000966. doi: 10.1136/bmjophth-2021-000966. eCollection 2022.
5
The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients.青光眼患者从1%布林佐胺和0.1%溴莫尼定转换为1%布林佐胺与0.1%溴莫尼定固定组合后的疗效、安全性及满意度
J Clin Med. 2021 Nov 10;10(22):5228. doi: 10.3390/jcm10225228.
6
Soft Contact Lenses as Drug Delivery Systems: A Review.软性隐形眼镜作为药物传递系统:综述。
Molecules. 2021 Sep 14;26(18):5577. doi: 10.3390/molecules26185577.
7
Inkjet Printed Textile Force Sensitive Resistors for Wearable and Healthcare Devices.喷墨打印纺织品力敏电阻器在可穿戴和医疗保健设备中的应用。
Adv Healthc Mater. 2021 Oct;10(20):e2100893. doi: 10.1002/adhm.202100893. Epub 2021 Jul 1.
8
In vivo drug delivery via contact lenses: The current state of the field from origins to present.通过隐形眼镜进行体内药物递送:该领域从起源到现在的现状
J Drug Deliv Sci Technol. 2021 Jun;63. doi: 10.1016/j.jddst.2021.102413. Epub 2021 Feb 18.
9
Review of glaucoma medication adherence monitoring in the digital health era.数字健康时代青光眼药物依从性监测综述
Br J Ophthalmol. 2023 Feb;107(2):153-159. doi: 10.1136/bjophthalmol-2020-317918. Epub 2021 Apr 15.
10
Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies.一种新型机电式眼部局部给药系统的临床评估:两项1期概念验证研究
Clin Ophthalmol. 2020 Jan 20;14:139-147. doi: 10.2147/OPTH.S221749. eCollection 2020.